Johnson & Johnson will no longer sell the Sedasys automated sedation system, according to MarketWatch.
Here are six things to know:
1. The Sedasys system automated the process of sedating patients prior to colon-cancer screenings.
2. The FDA approved the system in 2013, and it was initially considered an innovative, cost-saving new technology.
3. The sale and marketing of the system saw tremendous pushback from anesthesiologists who claimed that automating the sedation process could lead to patient safety issues.
4. Johnson & Johnson decided to stop selling the system as part of a broader restructuring of its medical device business.
5. According to a company insider, sales of the Sedasys system did not take off as J&J had expected.
6. The company announced the restructuring plan in January, which also includes the proposed elimination of about 3,000 jobs in the medical devices division.